To explore the role of B4GALT3 in the TIME, we first investigated the growth of four C57BL/6 strain tumor models with varying immunogenicity: breast adenocarcinoma E0771, colon carcinoma MC38, melanoma B16F10, and bladder carcinoma MB49. Here, B4GALT3 is linked to urinary bladder carcinoma.